Cambrex and AstraZeneca hold ceremony to mark long-term supply agreement at Karlskoga, Sweden facility.
Cambrex Corporation, a manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), held an opening ceremony Tuesday with AstraZeneca at its Karlskoga, Sweden site to mark the commencement of a long-term manufacturing agreement between the two companies for a key intermediate.
The announcement follows the completion in 2017 of both a large-scale, multi-purpose capacity expansion, which also includes hydrogenation capabilities, and a dedicated continuous flow production unit capable of producing multiple metric tons of high purity advanced intermediates per year at the Karlskoga facility.
“Cambrex was selected as our manufacturing partner on this long-term intermediate supply agreement as they clearly demonstrated a robust technically and commercially attractive solution, as well as having a good track record in terms of performance and delivery,” Juliette White, VP global external sourcing, AstraZeneca, commented at the ceremony.
“We will continue to invest in capabilities, technology, and appropriate capacity at the Karlskoga site in line with AstraZeneca’s ambitious targets and on-going customer demand,” Shawn Cavanagh, COO of Cambrex, said.
(Source: Cambrex Corporation)